BP
FTH

BNP Paribas’s Faeth Therapeutics FTH Stock Holding History

BNP Paribas’s Portfolio FTH Stock Details FTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7
Closed -$59 – 364
2025
Q4 		$59 Buy
+7
New +$68 ﹤0.01% 348

Other funds holding FTH

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

BNP Paribas's FTH Position: Q1 2026 in Review

BNP Paribas sold out of Faeth Therapeutics (FTH) in Q1 2026, closing a stake of 7 shares — an estimated $59 sold.

BNP Paribas first reported a position in FTH in Q4 2025 and held it in 1 quarter. The position peaked at $59 in Q4 2025. 30 funds tracked by Wall St. Rank hold FTH as of Q1 2026.

  • BNP Paribas reported no remaining Faeth Therapeutics position as of Q1 2026 after selling out during the quarter.
  • BNP Paribas sold 7 Faeth Therapeutics shares in Q1 2026, an estimated $59.
  • BNP Paribas first reported a position in Faeth Therapeutics in Q4 2025 and held it in 1 quarter.
  • BNP Paribas's Faeth Therapeutics position peaked at $59 in Q4 2025.
  • 30 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2026.

Based on BNP Paribas's 13F filing for Q1 2026, filed 12 May 2026.